Positive Interim R&D Results, Opening of New Laboratories, and Prestigious Awards Underline Growth Potential in Biotech

  Positive Interim R&D Results, Opening of New Laboratories, and Prestigious
 Awards Underline Growth Potential in Biotech Companies - Research Report on
               Gilead, Biogen Idec, Ariad, Incyte, and Sequenom

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 1, 2013

NEW YORK, July 1, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Gilead
Sciences Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Ariad
Pharmaceuticals Inc. (NASDAQ: ARIA), Incyte Corporation (NASDAQ: INCY), and
Sequenom Inc. (NASDAQ: SQNM). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Gilead Sciences Inc. Research Report

On June 17, 2013, Gilead Sciences Inc. (Gilead) announced interim results from
a single-arm, open-label Phase II study (Study 101-09) evaluating idelalisib
(formerly GS-1101), which is an investigational, targeted, oral inhibitor of
PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma
(iNHL) that is refractory (non-responsive) to rituximab and to
alkylating-agent-containing chemotherapy. Gilead reported that the
single-agent treatment with idelalisib achieved an overall response rate of
53.6%, with median duration of response of 11.9 months at this interim
analysis. "These data suggest that idelalisib has the potential to provide
durable disease control to this group of patients who have few if any
remaining conventional treatment options," said Gilles A. Salles, MD, PhD,
Professor of Medicine, Department of Hematology, Claude Bernard University,
Lyon-Sud Hospital Center, Pierre-Benite, France. The Full Research Report on
Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Biogen Idec Inc. Research Report

On June 24, 2013, Biogen Idec Inc. (Biogen Idec) announced that it will
release new data from a number of development and early-stage research
programs at the XXIV International Society on Thrombosis and Haemostasis
(ISTH) Congress. The Congress will be held from June 29, 2013 to July 4, 2013
in Amsterdam, Netherlands. Biogen Idec reported that researchers will present
33 abstracts on clinical and pre-clinical research in hemophilia. Glenn Piece,
M.D., Ph.D., Senior Vice President, Global Medical Affairs and Chief Medical
Officer at Biogen Idec, stated, "The robust research being showcased at ISTH
reflects our commitment to the community to address these unmet needs through
innovative research and science. This includes striving to bring the first
major advances in hemophilia treatment in more than fifteen years." The Full
Research Report on Biogen Idec Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WSReports.com/r/full_research_report/b35f_BIIB]


Ariad Pharmaceuticals Inc. Research Report

On June 18, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced that it has
received two Gold Stevie Awards at the recently concluded 11th Annual American
Business Awards in Chicago. Harvey J. Berger, M.D., Founder, Chairman and CEO
of Ariad, commented, "The recognition of ARIAD through these two Stevie Awards
at the same time represents the culmination of more than twenty years of
dedication to ARIAD's vision -- to transform the lives of cancer patients with
breakthrough medicines." Berger added, "All of our employees are to be
commended for their contributions that led to ARIAD being named Company of the
Year. Personally, I am humbled by the recognition as Pharmaceutical Executive
of the Year by the American Business Awards." Ariad received the awards in the
following categories: Company of the Year, Pharmaceuticals and Executive of
the Year, Pharmaceuticals. The Full Research Report on Ariad Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:


Incyte Corporation Research Report

On June 13, 2013, Incyte Corporation (Incyte) and Eli Lilly and Company
(Lilly) jointly announced the 52-week efficacy and safety data from the
open-label, long-term extension of the Phase 2b JADA study of baricitinib in
patients with active rheumatoid arthritis (RA). Incyte reported that
baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus
kinase (JAK) inhibitor being studied for use in the treatment of certain
autoimmune conditions, including RA. Peter Taylor, M.A., Ph.D., F.R.C.P.,
Norman Collisson Chair of Musculoskeletal Sciences in the Nuffield Department
of Orthopaedics, Rheumatology, and Musculoskeletal Sciences at the University
of Oxford, and steering Committee Member for the study, stated, "In this
clinical trial baricitinib showed statistically and clinically significant
improvements in the features of this condition, which were maintained
throughout a year of treatment. To date, baricitinib has demonstrated an
acceptable safety profile and side effects have generally been straightforward
to manage. These encouraging findings support further investigation of this
new drug in rheumatoid arthritis." The Full Research Report on Incyte
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Sequenom Inc. Research Report

On June 12, 2013, Sequenom Inc. (Sequenom) announced that its wholly-owned
subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has opened
its new laboratory in Raleigh-Durham, North Carolina. Sequenom reported that
the laboratory is now processing patient samples commercially. William Welch,
President and COO of Sequenom, said, "We are excited about the opening in
North Carolina of our third US-based laboratory location. Our investment in
establishing this new presence on the East coast will allow us to better meet
the needs of health care providers by providing critical additional capacity
and geographic back-up needed to address the rapidly growing adoption of our
testing services." The Full Research Report on Sequenom Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.